Author: Antoniu, Sabina

Source: Expert Opinion on Pharmacotherapy, Volume 10, Number 7, May 2009 , pp. 1231-1233(3)

Publisher: Informa Healthcare

Abstract:

Background: Severe asthma with fungal sensitivity (SAFS) is a recently described form of asthma that is difficult to treat with conventional inhaled corticosteroids. Antifungal therapies such as itraconazole might be an option. Objective: To discuss the data from a study evaluating efficacy and safety of itraconazole therapy in SAFS. Methods/results: Itraconazole therapy was found to improve quality of life and reduce immune response, with no impact on lung function. Conclusions: Itraconazole may be a promising therapy in SAFS, provided its potential of reducing airway inflammation is further documented.

Keywords: allergic bronchopulmonary aspergillosis; fungal sensitisation; itraconazole; severe asthma

Document Type: Research article

DOI: http://dx.doi.org/10.1517/14656560902918319

Publication date: 2009-05-01

More about this publication?

• Editorial Board
• Information for Authors
• Subscribe to this Title
• Terms & Conditions
• ingentaconnect is not responsible for the content or availability of external websites

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Antoniu, Sabina

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers